6XP.F XSPRAY PHARMA AB

Healthcare Biotechnology Frankfurt Exchange
1.17 EUR
Close of Nov 11, 2026
0.7760 3.14
Market cap
EUR 55.6M
P/E
-
P/B
1.01x
ROE
-25.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 6XP.F undervalued?

Graham number

The Graham number of XSPRAY PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

XSPRAY PHARMA AB fundamental analysis

No fundamental analysis for XSPRAY PHARMA AB yet.

XSPRAY PHARMA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About XSPRAY PHARMA AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib fo…

Full company profile